 period if intracranial hemorrhage has been
excluded. There are no randomized trial data for determining whether intravenous heparin administration is superior to antiplatelet therapy in preventing early recurrent
stroke in patients with stroke in evolution or crescendo
TIAs. Two trials compared low-molecular-weight heparin
vs aspirin monotherapy in acute stroke patients where antiplatelet/antithrombotic therapy was commenced
within 48 hours of onset of symptoms. There